Medline Inc. shares advanced Monday as Wall Street analysts struck a bullish tone on the medical supplier’s business model and growth prospects following its $7.2 billion IPO last month.
Twenty seven firms tracked by Bloomberg initiated coverage, with 22 buy-equivalent ratings. Analysts set an average 12-month price target of $47.12 per share, implying a 12% upside from Friday’s close, pointed to Medline’s scale and vertically integrated manufacturing model as well as tailwinds from an aging population.
Shares of Medline climbed as much as 6.3% on Monday, adding to gains since its initial public offering, which was the largest in 2025 ...
